Oppenheimer Analysts Give ADMA Biologics (ADMA) a $13.00 Price Target

ADMA Biologics (NASDAQ:ADMA) has been assigned a $13.00 price objective by investment analysts at Oppenheimer in a report issued on Wednesday, October 17th. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s target price suggests a potential upside of 147.15% from the company’s current price.

A number of other research firms have also weighed in on ADMA. Maxim Group upped their target price on shares of ADMA Biologics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, July 26th. BidaskClub upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. Raymond James reiterated a “buy” rating and issued a $10.00 price objective (down previously from $11.00) on shares of ADMA Biologics in a research note on Friday, October 12th. Chardan Capital began coverage on shares of ADMA Biologics in a research note on Monday, July 30th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, ValuEngine upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Thursday, July 26th. Eight equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $11.58.

Shares of NASDAQ ADMA traded down $0.48 during trading on Wednesday, hitting $5.26. 177,456 shares of the company traded hands, compared to its average volume of 226,392. ADMA Biologics has a fifty-two week low of $2.10 and a fifty-two week high of $6.96. The firm has a market capitalization of $266.97 million, a P/E ratio of -2.75 and a beta of 2.28. The company has a current ratio of 10.65, a quick ratio of 8.88 and a debt-to-equity ratio of 0.79.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, November 8th. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.02). ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. The business had revenue of $4.23 million during the quarter, compared to analyst estimates of $5.39 million. Equities research analysts forecast that ADMA Biologics will post -1.36 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of ADMA Biologics by 2,295.0% during the 2nd quarter. BlackRock Inc. now owns 970,839 shares of the biotechnology company’s stock valued at $4,378,000 after acquiring an additional 930,303 shares during the period. 683 Capital Management LLC boosted its holdings in ADMA Biologics by 9.9% in the 2nd quarter. 683 Capital Management LLC now owns 885,000 shares of the biotechnology company’s stock worth $3,991,000 after buying an additional 80,000 shares during the period. Stonepine Capital Management LLC bought a new position in ADMA Biologics in the 2nd quarter worth approximately $3,751,000. Millennium Management LLC boosted its holdings in ADMA Biologics by 305.2% in the 1st quarter. Millennium Management LLC now owns 273,621 shares of the biotechnology company’s stock worth $1,259,000 after buying an additional 206,088 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in ADMA Biologics by 54.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 228,999 shares of the biotechnology company’s stock worth $1,422,000 after buying an additional 81,003 shares during the period. 55.07% of the stock is owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

See Also: What is Considered a Good Return on Equity (ROE)?

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply